心脏骤停自主循环恢复后临时机械循环支持:系统评价与荟萃分析
该系统评价与荟萃分析纳入14项随机对照试验、共1842例急性心肌梗死相关心源性休克(AMI-CS)患者,其中762例在院内外心脏骤停后达到自主循环恢复(ROSC)。在ROSC后患者中,机械循环支持(MCS)组最长随访生存率为46%,标准治疗组为41%,RR 1.10(95%CI 0.94-1.29),p=0.23,I²=0.0%,差异未达统计学显著。贝叶斯分析显示任何生存获益的后验概率为88%,临床相关获益(>5%)的后验概率为56%。在无心脏骤停或心脏骤停持续时间<10分钟的患者中,MCS改善生存(56% vs 45%;RR 1.25,95%CI 1.06-1.47;p=0.007)。MCS与器械相关并发症增加相关。
要点
- ROSC后AMI-CS患者中,MCS组最长随访生存率46% vs 标准治疗组41%,RR 1.10(95%CI 0.94-1.29),差异未达统计学显著。
- 贝叶斯分析:MCS任何生存获益的后验概率88%,临床相关获益(>5%)的后验概率56%。
- 无心脏骤停或心脏骤停持续时间<10分钟的患者中,MCS改善生存(56% vs 45%;RR 1.25,95%CI 1.06-1.47;p=0.007)。
- MCS与器械相关并发症增加相关。
- 作者认为未来研究应针对缺氧缺血性脑损伤风险更低的、更仔细筛选的患者。
适用人群与场景
- 14项随机对照试验纳入的1842例急性心肌梗死相关心源性休克(AMI-CS)患者,其中762例在院内外心脏骤停后达到自主循环恢复(ROSC)。
- 亚组分析涉及无心脏骤停或心脏骤停持续时间<10分钟的患者。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入14项随机对照试验,共1842例AMI-CS患者,其中762例为心脏骤停后ROSC患者。
- 主要终点:MCS组最长随访生存率46% vs 标准治疗组41%,RR 1.10(95%CI 0.94-1.29),p=0.23,I²=0.0%,差异未达统计学显著。
- 贝叶斯分析:RR 1.13(95% CrI 0.90-1.44),任何生存获益(绝对风险差>0%)的后验概率88%,临床相关获益(>5%)的后验概率56%。
- 亚组:无心脏骤停或心脏骤停持续时间<10分钟的患者中,MCS组生存率56% vs 标准治疗组45%,RR 1.25(95%CI 1.06-1.47),p=0.007。
- 安全性:MCS与器械相关并发症增加相关。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入14项随机对照试验。
对床旁实践的改变
- 在未筛选的心脏骤停后AMI-CS患者中,常规使用临时MCS未改善生存且增加器械相关并发症。
- 在无心脏骤停或心脏骤停持续时间<10分钟的患者中,MCS改善生存(56% vs 45%;RR 1.25,95%CI 1.06-1.47;p=0.007)。
- 作者认为未来研究应针对缺氧缺血性脑损伤风险更低的、更仔细筛选的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Shock with cardiogenic involvement is common after return of spontaneous circulation (ROSC) following cardiac arrest. Temporary mechanical circulatory support (MCS) is increasingly used in acute myocardial infarction-related cardiogenic shock (AMI-CS), but its efficacy in post-cardiac arrest patients remains uncertain.
METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing MCS (extracorporeal membrane oxygenation, intra-aortic ballon pump, or microaxial flow pump) versus standard care after ROSC. PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched through June 19, 2025. The primary outcome was survival at the longest follow-up. Frequentist estimates were complemented by a Bayesian meta-analysis.
RESULTS: Fourteen RCTs enrolling 1,842 AMI-CS patients were identified, of whom 762 had achieved ROSC after in- or out-of-hospital cardiac arrest. In these patients, MCS did not improve survival at the longest follow-up (46 % with MCS vs 41 % with standard care; RR 1.10 [95 % CI, 0.94-1.29]; p = 0.23; I2 = 0.0 %). Bayesian analysis (RR 1.13 [95 % CrI, 0.90-1.44]) showed an 88 % posterior probability of any survival benefit (absolute risk difference > 0 %) and a 56 % probability of a clinically relevant benefit (>5 %). In patients with no or cardiac arrest duration < 10 min, MCS improved survival (56 % vs 45 %; RR 1.25 [95 % CI, 1.06-1.47]; p = 0.007). MCS was associated with increased device-related complications.
CONCLUSIONS: Routine use of temporary MCS does not improve survival in unselected cardiac arrest patients with AMI-CS and increased complication rates. Future research should target more carefully selected patients with lower risk of hypoxic-ischemic brain injury.
REVIEW REGISTRATION: PROSPERO CRD42024566810.
参考来源
- Scquizzato T, Grunau B, Fernando SM, et al. Temporary mechanical circulatory support after return of spontaneous circulation following cardiac arrest: a systematic review and meta-analysis. Resuscitation. 2025. PMID: 41232590. doi:10.1016/j.resuscitation.2025.110893
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。